Methods and compositions involving MDA-7
AssigneesBoard of Regents, The University of Texas System, Introgen Therapeutics, Inc.
InventorsSunil Chada, John Mumm, Rajagopal Ramesh, Abner Mhashilkar, Raymond Meyn, Elizabeth Grimm
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods involving MDA-7. More specifically, the present invention is directed to diagnostic, prognostic, and therapeutic treatment compositions and methods for treatment of cancer and other angiogenesis-related disorders (anti-angiogenesis therapy). The present invention is also directed to methods of purification of MDA-7.
Claims49
A method for purifying MDA-7 protein from a cell comprising subjecting a cell extract or supernatant comprising MDA-7 protein to affinity chromatography.
A method for purifying active, glycosylated, secreted MDA-7 protein from a cell comprising:
- a) subjecting a cell extract or supernatant comprising secreted MDA-7 protein to affinity chromatography involving an anti-MDA antibody;
- b) subjecting the affinity chromatography-purified MDA-7 protein to size resolution purification;
- and,
- c) subjecting the size resolution-purified MDA-7 to anion exchange chromatography.
Purified MDA-7 protein, wherein the protein is active.
A method for radiosensitizing a cancer cell comprising administering to the cell an effective amount of an adenovirus vector comprising a nucleic acid encoding MDA-7, wherein the nucleic acid is under the control of a promoter operable in the cell.
A method of treating cancer in a patient comprising administering to the patient an NF-κB inhibitor and a composition comprising either MDA-7 protein or an adenovirus vector comprising a nucleic acid encoding MDA-7 under the control of a promoter.
A protein comprising amino acids 100 to 206 of SEQ ID NO:2 and an endoplasmic reticulum targeting sequence.
A method for inhibiting or preventing local invasiveness and/or metastasis of cancer in a patient, comprising administering to the patient an effective amount of a pharmaceutically acceptable composition comprising MDA-7 protein, wherein the MDA-7 inhibits or prevents the local invasiveness and/or metastasis of the cancer.
A method for inhibiting or preventing local invasiveness and/or metastasis of cancer in a patient, comprising administering to the patient an effective amount of a pharmaceutically acceptable composition comprising a polynucleotide encoding an MDA-7 protein, wherein the MDA-7 protein inhibits or prevents the local invasiveness and/or metastasis of the cancer.
Dependencies are inferred from the claim text.